Who makes LCB01-0371 400mg, BID?

LCB01-0371 400mg, BID is developed by LigaChem Biosciences, Inc..

What development phase is LCB01-0371 400mg, BID in?

LCB01-0371 400mg, BID is in Phase 2.

Last reviewed 2026-05-15 · How we verify

LCB01-0371 400mg, BID

LigaChem Biosciences, Inc. · Phase 2 active Small molecule

At a glance

Generic name	LCB01-0371 400mg, BID
Also known as	LCB01-0371
Sponsor	LigaChem Biosciences, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LCB01-0371 400mg, BID CI brief — competitive landscape report
LCB01-0371 400mg, BID updates RSS · CI watch RSS
LigaChem Biosciences, Inc. portfolio CI